Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug pric­ing — and here are the block­busters she’s tar­get­ing first

Nan­cy Pelosi’s drug pric­ing bill may have sparked some in­dus­tri­al strength headaches on the mon­ey side of bio­phar­ma, but Eliz­a­beth War­ren seems de­ter­mined to be­come bio­phar­ma’s Night­mare on Penn­syl­va­nia Av­enue.

War­ren, one of the top-ranked can­di­dates for the De­mo­c­ra­t­ic pres­i­den­tial nom­i­na­tion back­ing Medicare for all, is cir­cu­lat­ing a new plan that promis­es to break the in­dus­try’s grip on drug prices — and she has some very spe­cif­ic ex­am­ples of how she would do it.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE